Tri Locum Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Tri Locum Partners’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-28,470	Closed	-$3.06M	–	84
2023 Q1	$3.06M	Buy	+28,470	New	+$3.28M	0.93%	33
2022 Q4	–	Sell	-123,599	Closed	-$8.01M	–	95
2022 Q3	$7.29M	Sell	123,599 -194,159	-61%	-$8.88M	2%	18
2022 Q2	$8.97M	Buy	317,758 +168,692	+113%	+$4.89M	3.67%	10
2022 Q1	$5.63M	Buy	+149,066	New	+$5.89M	2.2%	23

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Tri Locum Partners's RXDX Position: Q2 2023 in Review

Tri Locum Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 28,470 shares — an estimated $3.06M sold.

Tri Locum Partners first reported a position in RXDX in Q1 2022 and held it in 4 quarters. The position peaked at $8.97M in Q2 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Tri Locum Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Tri Locum Partners sold 28,470 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.06M.
Tri Locum Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Tri Locum Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $8.97M in Q2 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.